

Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021

Shaun J. Grannis, MD¹; Elizabeth A. Rowley, DrPH²; Toan C. Ong, PhD³; Edward Stenehjem, MD⁴; Nicola P. Klein, MD, PhD⁵; Malini B. DeSilva, MD⁶; Allison L. Naleway, PhD⁷; Karthik Natarajan, PhD⁸; Mark G. Thompson, PhD⁹; VISION Network

Data on COVID-19 vaccine effectiveness (VE) since the B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating strain in the United States are limited (1–3). CDC used the VISION Network* to examine medical encounters (32,867) from 187 hospitals and 221 emergency departments (EDs) and urgent care (UC) clinics across nine states during June–August 2021, beginning on the date the Delta variant accounted for >50% of sequenced isolates in each medical facility's state. VISION Network methods have been published (4).

Eligible medical encounters were defined as those among adults aged ≥18 years who had received SARS-CoV-2 molecular testing (primarily reverse transcription–polymerase chain reaction assay within 14 days before or 72 hours after the admission or encounter) and a COVID-19–like illness discharge diagnosis. Vaccination status was documented in electronic health records and immunization registries. Full vaccination was defined as receipt of the second dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) mRNA vaccines, or a single dose of Ad26.COV2 (Janssen [Johnson & Johnson]) vaccine ≥14-days before the testing or encounter date. Patients who had received no COVID-19 vaccine doses were considered unvaccinated. Patients who had received 1 mRNA dose only or had received the second dose <14 days before testing or encounter date were excluded. VE was estimated using a test-negative design, calculating the odds of receiving a positive SARS-CoV-2 test result comparing

fully vaccinated and unvaccinated patients (referent group). VE was adjusted for age, geographic region, calendar time (days from January 1 to medical event), and virus circulation, and weighted for inverse propensity to be vaccinated or unvaccinated (calculated separately for each VE model). VE estimates with 95% confidence intervals (CIs) that did not overlap were considered statistically different. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.[†]

Among fully vaccinated patients, the proportion who had received each vaccine product among hospitalizations and ED/UC encounters, respectively, were Pfizer-BioNTech, 55.3% and 53.6%; Moderna, 38.8% and 36.1%; and Janssen, 6.0% and 10.3%. The median interval from becoming fully vaccinated to the hospital admission or ED/UC encounter, respectively, were 110 and 93 days (Pfizer-BioNTech), 106 and 96 days (Moderna), and 94 and 94 days (Janssen).

Among adults hospitalized with COVID-19–like illness (14,636; median patient age = 65 years, interquartile range [IQR] = 48–77 years), laboratory-confirmed SARS-CoV-2 infections were identified among 18.9% (1,316 of 6,960) of unvaccinated and 3.1% (235 of 7,676) of fully vaccinated patients. Overall, VE against COVID-19 hospitalization was 86% (95% CI = 82%–89%). VE was significantly lower among adults aged ≥75 years (76%) than among those aged 18–74 years (89%) (Table). The difference in VE point estimates between age groups was similar for Pfizer-BioNTech and Moderna vaccines. Across all ages, VE was significantly higher among Moderna vaccine recipients (95%) than among Pfizer-BioNTech (80%) or Janssen (60%) vaccine recipients.

* Funded by CDC, the VISION network includes Columbia University Irving Medical Center (New York), HealthPartners (Minnesota and Wisconsin), Intermountain Healthcare (Utah), Kaiser Permanente Northern California (California), Kaiser Permanente Northwest (Oregon and Washington), Regenstrief Institute (Indiana), and University of Colorado (Colorado).

[†] 45 C.F.R. part 46; 21 C.F.R. part 56.



TABLE. COVID-19 vaccine effectiveness* against laboratory-confirmed COVID-19–associated emergency department and urgent care clinic encounters and hospitalizations† among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance,‡ by outcome, age group, and vaccine — nine states,¶ June–August 2021

Outcome	Total	No. of SARS-CoV-2–positive tests (row %)	VE, % (95% CI)
All adults (aged ≥18 yrs), any COVID-19 vaccine			
COVID-19 hospitalizations			
Unvaccinated (ref)	6,960	1,316 (18.9)	—
Fully vaccinated**	7,676	235 (3.1)	86 (82–89)
COVID-19 ED/UC encounters			
Unvaccinated (ref)	10,872	3,145 (28.9)	—
Fully vaccinated**	7,359	512 (7.0)	82 (81–84)
COVID-19 hospitalizations, any COVID-19 vaccine, by age			
Age group = 18–74 yrs			
Unvaccinated (ref)	5,708	1,185 (20.8)	—
Fully vaccinated**	4,551	134 (2.9)	89 (85–92)
Age group = ≥75 yrs			
Unvaccinated (ref)	1,252	131 (10.5)	—
Fully vaccinated**	3,125	101 (3.2)	76 (64–84)
COVID-19 hospitalizations by COVID-19 vaccine			
BNT162b2 (Pfizer-BioNTech)			
Unvaccinated (ref)	6,960	1,316 (18.9)	—
Fully vaccinated**	4,243	135 (3.2)	80 (73–85)
mRNA-1273 (Moderna)			
Unvaccinated (ref)	6,960	1,316 (18.9)	—
Fully vaccinated**	2,975	70 (2.4)	95 (92–97)
Ad26.COV2.S (Janssen)			
Unvaccinated (ref)	6,960	1,316 (18.9)	—
Fully vaccinated**	458	30 (6.5)	60 (31–77)
COVID-19 ED/UC encounters by COVID-19 vaccine			
BNT162b2 (Pfizer-BioNTech)			
Unvaccinated (ref)	10,872	3,145 (28.9)	—
Fully vaccinated**	3,946	314 (8.0)	77 (74–80)
mRNA-1273 (Moderna)			
Unvaccinated (ref)	10,872	3,145 (28.9)	—
Fully vaccinated**	2,656	98 (3.7)	92 (89–93)
Ad26.COV2.S (Janssen)			
Unvaccinated (ref)	10,872	3,145 (28.9)	—
Fully vaccinated**	757	100 (13.2)	65 (56–72)

Abbreviations: CI = confidence interval; ED = emergency department; HHS = U.S. Department of Health and Human Services; Janssen = Johnson & Johnson vaccine; Ref = referent group; UC = urgent care; VE = vaccine effectiveness.

* VE was estimated using a test-negative design, adjusted for age, geographic region, calendar time (cubic spline with quartile knots), and virus circulation (percentage of SARS-CoV-2–positive results from testing within the counties surrounding the facility on the date of the event) and weighted for inverse propensity to be vaccinated or unvaccinated (calculated separately for each of the 10 VE models) using facility characteristics, sociodemographics, and underlying medical conditions.

† Medical events with a discharge code consistent with COVID-19–like illness were included, such as acute respiratory illness (e.g., COVID-19, respiratory failure, or pneumonia) or related signs or symptoms (cough, fever, dyspnea, vomiting, or diarrhea) using diagnosis codes from the ninth and tenth revisions of the *International Classification of Diseases*. Clinician-ordered molecular assays (e.g., real-time reverse transcription–polymerase chain reaction) for SARS-CoV-2 occurring ≤14 days before to <72 hours after hospital admission or ED/UC encounter were included.

‡ Medical events occurred when Delta variant was predominant (>50%) in each state, according to data from network partners, CDC COVID data tracker (<https://covid.cdc.gov>), and HHS Protects Public Data Hub (<https://protect-public.hhs.gov>).

¶ Partners contributing both ED/UC encounters and hospitalizations in 2021 were in Indiana (range of earliest to latest medical event: July 3–26), Oregon and Washington (June 30–August 4), and Utah (June 1–July 24). Partners contributing hospitalizations only were in California (June 23–August 4), Colorado (June 3–July 20), Minnesota and Wisconsin (July 1–August 2), and New York (June 30–July 25).

** Full vaccination was defined as index testing or admission date ≥14 days after second dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) or after a single dose of Ad26.COV2 (Janssen) vaccines.

Among adults with ED/UC encounters for COVID-19–like illness (18,231; median patient age = 43 years, IQR = 29–62 years), laboratory-confirmed SARS-CoV-2 infections were identified among 28.9% (3,145 of 10,872) of unvaccinated and 7.0% (512 of 7,359) of fully vaccinated patients. VE against COVID-19 ED/UC encounters was 82% (95% CI = 81%–84%). VE was highest among Moderna

vaccine recipients (92%), followed by Pfizer-BioNTech vaccine recipients (77%), and was lowest (65%) for Janssen vaccine recipients (Table).

In this multistate interim analysis of 32,867 medical encounters among adults of all ages during June–August 2021, when the Delta variant was predominant in the United States, VE of all three authorized COVID-19 vaccines combined remained

high against hospitalization (86%) and ED/UC encounters (82%). These overall VE estimates were similar to those during the months before Delta became predominant (2,4). However, VE against COVID-19 hospitalization among adults aged ≥ 75 years was significantly lower than that among adults aged < 75 years, which had not been observed previously from this data source (4). This moderate decline should be interpreted with caution and might be related to changes in SARS-CoV-2, waning of vaccine-induced immunity with increased time since vaccination, or a combination of factors. Differences in VE between the two mRNA vaccines, which had not been observed previously in the VISION Network (4), are consistent with another recent finding.[§] Further examination of the magnitude and sources of product-specific VE differences are also warranted.

The findings in this report are subject to at least three limitations. First, VE by time since vaccination was not examined; further evaluation of possible waning of vaccine protection is currently underway. Second, VE for partial vaccination was not assessed. Finally, although the facilities in this study serve heterogeneous populations in nine states, the findings might not be generalizable to the U.S. population.

These findings reaffirm the high protection of COVID-19 vaccines against moderate and severe COVID-19 resulting in ED, UC, and hospital visits and underscore the importance of full COVID-19 vaccination and continued benefits of COVID-19 vaccination during Delta variant predominance.

[§]<https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v2>

Acknowledgments

Catherine H. Bozio, Sue Reynolds, Jill Ferdinands, Palak Patel, Eric P. Griggs, Rachael M. Porter, Lenee Blanton, Andrea Steffens, Natalie Olson, Stephanie J. Schrag, Jennifer R. Verani, Alicia M. Fry, Eduardo Azziz-Baumgartner, CDC COVID-19 Response Team; Kristin Dascomb, Nancy Grisel, Julie Arndorfer, Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare; Brian E. Dixon, William F. Fadel, Nimish Ramesh Valvi, Peter J. Embi, Center for Biomedical Informatics, Regenstrief Institute;

Sarah W. Ball, Rebecca J. Birch, Matthew E. Levy, Maria Demarco, Yan Zhuang, Patricia Shifflett, Westat; Stephanie A. Irving, Center for Health Research, Kaiser Permanente Northwest; Suchitra Rao, Michelle A. Barron, Department of Medicine, University of Colorado; Elyse O. Kharbanda, HealthPartners Institute; Jungmi Han, Department of Biomedical Informatics, Columbia University; Ned Lewis, Kristin Goddard, Bruce Fireman, Ousseny Zerbo, Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California; Anupam Kharbanda, Children's Minnesota; Manjusha Gaglani, Baylor Scott & White Health, Texas A&M University College of Medicine.

Corresponding author: Mark G. Thompson, isq8@cdc.gov, for the VISION Network.

¹Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana; ²Westat, Rockville, Maryland; ³Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado; ⁴Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah; ⁵Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California; ⁶HealthPartners Institute, Minneapolis, Minnesota; ⁷Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon; ⁸Department of Biomedical Informatics, Columbia University, New York, New York; ⁹CDC COVID-19 Response Team.

References

1. Thompson MG, Burgess JL, Naleway AL, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. *N Engl J Med* 2021;385:320–9. PMID:34192428 <https://doi.org/10.1056/NEJMoa2107058>
2. Tenforde MW, Self WH, Naioti EA, et al.; IVY Network Investigators; Ivy Network. Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults—United States March–July 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:1156–62. PMID:34437524 <https://doi.org/10.15585/mmwr.mm7034e2>
3. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet* 2021;397:1819–29. PMID:33964222 [https://doi.org/10.1016/S0140-6736\(21\)00947-8](https://doi.org/10.1016/S0140-6736(21)00947-8)
4. Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings. *N Engl J Med* 2021 Epub September 8, 2021. PMID:34496194 <https://doi.org/10.1056/NEJMoa2110362>

Readers who have difficulty accessing this PDF file may access the HTML file at https://www.cdc.gov/mmwr/volumes/70/wr/mm7037e2.htm?s_cid=mm7037e2_w. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop V25-5, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30329-4027 or to mmwrq@cdc.gov.